Sionna Therapeutics (SION) Other financing activities (2024 - 2026)

Sionna Therapeutics (SION) reported Other financing activities of $2.2 million for Q1 2026, down 98.9% sequentially from $202.1 million in Q2 2025.

Sionna Therapeutics (SION) Other financing activities (2024 - 2026) Analysis & Trends

Sionna Therapeutics (SION) has 3 years of Other financing activities data on file, last reported at $2.2 million in Q1 2026.

For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $204.3 million (changed N/A YoY), and the FY2025 full-year result was $202.1 million, changed N/A from the prior year.
Other financing activities fell to $2.2 million in Q1 2026, from $202.1 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $202.1 million in Q2 2025 to a low of -$116000.0 in Q4 2024.
A 3-year average of $40.9 million and a median of $73000.0 in 2024 frame the typical range for Other financing activities.
Peak annual rise in Other financing activities reached 469832.56% in 2025, while the deepest fall reached 469832.56% in 2025.
Tracing SION's Other financing activities over 3 years: stood at -$116000.0 in 2024, then surged by 174299.14% to $202.1 million in 2025, then tumbled by 98.9% to $2.2 million in 2026.
Business Quant data shows SION's Other financing activities at $2.2 million in Q1 2026, $202.1 million in Q2 2025, and -$116000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Sionna Therapeutics	1.98 Bn	1.98 Bn	-

Download Data